This study focuses on patients with Malignancies, which is a general term for cancers, that have specific genetic changes known as KRAS, BRAF, or other RAS/MAPK mutations. These mutations are abnormal changes in the genes that control how cells grow and divide. The purpose of the study is to evaluate the safety and effectiveness of the drug S-241656, both when used alone and when combined with other cancer treatments.
The medications being studied include S-241656, which is taken as an oral tablet, and several other drugs administered through an intravenous method, which means they are delivered directly into a vein. These other medications include oxaliplatin, cetuximab, panitumumab, gemcitabine, paclitaxel, irinotecan, fluorouracil, and folinic acid. During the study, different doses of these treatments may be used to determine the most appropriate amount for patients.
The study is divided into two main stages. In the first stage, the focus is on finding the safest dose of the medication. In the second stage, the study looks at how well the treatment works to shrink or control the cancer. Throughout the process, the way the body processes the medicine is also observed.
Denmark 
France 
Italy 
Spain 
